Keiya Ozawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keiya Ozawa has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Akihiro Kume
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi 329-0498, Japan
5 shared publicationsMasashi Urabe
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi
5 shared publicationsHiroaki Mizukami
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi 329–0498, Japan
3 shared publicationsYoji Ogasawara
Division of Genetic Therapeutics, Jichi Medical School1 and CREST, Japan Science and Technology Corporation (JST)2, 3311-1 Yakushiji, Minamikawachi-machi, Tochigi 329-0498, Japan
3 shared publicationsJohn Monahan
Avigen, Inc., Alameda, California, USA
2 shared publicationsKatsuhiro Kogure
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi
2 shared publications
Latest Publications
- 28 October 2002
- Published by Wiley in The Journal of Gene Medicine
- Vol. 5 (3) , 175-181
In vivo expansion of transduced murine hematopoietic cells with a selective amplifier gene
- 28 October 2002
- Published by Wiley in The Journal of Gene Medicine
- Vol. 5 (3) , 175-181
In vivo expansion of transduced murine hematopoietic cells with a selective amplifier gene
- 30 August 2002
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 35 (4) , 365-367
Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse
- 30 August 2002
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 35 (4) , 365-367
Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse
- 1 July 2001
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 285 (4) , 891-896
Reversible Integration of the Dominant Negative Retinoid Receptor Gene for ex Vivo Expansion of Hematopoietic Stem/Progenitor Cells
- 1 July 2001
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 285 (4) , 891-896
Reversible Integration of the Dominant Negative Retinoid Receptor Gene for ex Vivo Expansion of Hematopoietic Stem/Progenitor Cells
- 1 May 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 73 (4) , 469-475
Targeted Integration of Foreign DNA Into a Defined Locus on Chromosome 19 in K562 Cells Using AAV-Derived Components
- 1 May 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 73 (4) , 469-475
Targeted Integration of Foreign DNA Into a Defined Locus on Chromosome 19 in K562 Cells Using AAV-Derived Components
- 1 January 2000
- Published by Springer Nature
- No. 58,p. 181-191
Gene therapy of Parkinson’s disease using Adeno-Associated Virus (AAV) vectors
Parkinson’s disease (PD) is characterized by the progressive loss of the dopaminergic neurons in the substantia nigra and a severe decrease in dopamine in the striatum. A promising approach to the gene theraphy of PD is instratiatal expression of dopamine-synthesizing enzymes [tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC)]. The most appropiate gene-delivery vehicles for neurons are adeno-associated virus (AAV) vectors, which are derived from non-pathogenic virus. Therefore, TH and AADC genes were introduced into the striatum in the lesioned side using separate AAV vectors in parkinsonian rats, and the coexpression of TH and AADC resulted in better behavorial recovery compared with TH alone. Another strategy for gene therapy of PD is the protection of dopaminergic neurons in the substantia nigra using an AAV vector containing a glial cell line-derived neurotrophic factor (GDNF) gene. Combination of dopamine-supplement gene therapy and GDNF gene therapy would be a logical approach to the treatment of PD.
- 1 January 2000
- Published by Springer Nature
- No. 58,p. 181-191
Gene therapy of Parkinson’s disease using Adeno-Associated Virus (AAV) vectors
Parkinson’s disease (PD) is characterized by the progressive loss of the dopaminergic neurons in the substantia nigra and a severe decrease in dopamine in the striatum. A promising approach to the gene theraphy of PD is instratiatal expression of dopamine-synthesizing enzymes [tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC)]. The most appropiate gene-delivery vehicles for neurons are adeno-associated virus (AAV) vectors, which are derived from non-pathogenic virus. Therefore, TH and AADC genes were introduced into the striatum in the lesioned side using separate AAV vectors in parkinsonian rats, and the coexpression of TH and AADC resulted in better behavorial recovery compared with TH alone. Another strategy for gene therapy of PD is the protection of dopaminergic neurons in the substantia nigra using an AAV vector containing a glial cell line-derived neurotrophic factor (GDNF) gene. Combination of dopamine-supplement gene therapy and GDNF gene therapy would be a logical approach to the treatment of PD.
- 1 September 1999
- Published by Microbiology Society in Journal of General Virology
- Vol. 80 (9) , 2477-2480
Highly regulated expression of adeno-associated virus large Rep proteins in stable 293 cell lines using the Cre/loxP switching system
Since the Rep proteins of adeno-associated virus (AAV) are harmful to cells, it is difficult to obtain stable cell lines that express them constitutively. In this study, stable 293 cell lines were obtained in which large Rep expression was inducible by using the Cre/loxP switching system. To determine the function of the induced Rep proteins, the packaging capacity was examined after supplementation with a plasmid expressing small Rep and Cap proteins. A significant amount of recombinant AAV (5·5×108 vector particles per 10 cm dish) was produced by transfection with a vector plasmid and infection with Cre-expressing recombinant adenovirus, indicating that the large Rep proteins retained the function required for packaging. These findings indicate that large Rep protein expression can be strictly regulated by the Cre/loxP system and will also serve as a basis for the development of an efficient AAV-packaging cell line.
- 1 September 1999
- Published by Microbiology Society in Journal of General Virology
- Vol. 80 (9) , 2477-2480
Highly regulated expression of adeno-associated virus large Rep proteins in stable 293 cell lines using the Cre/loxP switching system
Since the Rep proteins of adeno-associated virus (AAV) are harmful to cells, it is difficult to obtain stable cell lines that express them constitutively. In this study, stable 293 cell lines were obtained in which large Rep expression was inducible by using the Cre/loxP switching system. To determine the function of the induced Rep proteins, the packaging capacity was examined after supplementation with a plasmid expressing small Rep and Cap proteins. A significant amount of recombinant AAV (5·5×108 vector particles per 10 cm dish) was produced by transfection with a vector plasmid and infection with Cre-expressing recombinant adenovirus, indicating that the large Rep proteins retained the function required for packaging. These findings indicate that large Rep protein expression can be strictly regulated by the Cre/loxP system and will also serve as a basis for the development of an efficient AAV-packaging cell line.
- Open Access
- 1 July 1999
- Published by Wiley in The Journal of Gene Medicine
- Vol. 1 (4) , 236-244
A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells
- 1 July 1999
- Published by Wiley in The Journal of Gene Medicine
- Vol. 1 (4) , 236-244
Open AccessA selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells
- 1 April 1999
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 90 (4) , 476-483
Efficient Production of Adeno‐associated Virus Vectors Using Split‐type Helper Plasmids
Adeno‐associated virus (AAV) vectors are potentially useful vehicles for the delivery of therapeutic genes into human cells. To determine the optimal expression pattern of AAV proteins (Rep78, Rep68, Rep52, Rep40, and Cap proteins) for packaging the recombinant AAV genome, helper plasmids were split into two portions. In this study, two sets of split‐type helper plasmids were prepared; i.e., 1) a Rep expression plasmid (pRep) and Cap expression plasmid (pCap), and 2) a large Rep expression plasmid (pR78/68) and small Rep plus Cap expression plasmid (pR52/40Cap). When AAV vectors were produced using these sets of split‐type helper plasmids at various ratios, the optimal ratio of (large) Rep expression plasmid and Cap expression plasmid was 1 to 9 for both sets. More importantly, the titers were comparable to or even higher than that of a conventional helper plasmid (pIM45) (4.9±2.1×1011 vector particles/10 cm dish for pRep and pCap; 2.9±1.6×1011 vector particles/10 cm dish for pR78/68 and pR52/40Cap; and 1.8±0.16×1011 particles/10 cm dish for pIM45). Western analysis of AAV proteins suggests that the expression of a relatively small amount of large Rep and a large amount of Cap is important for optimal vector production. The present study shows that the AAV helper plasmid can be split without losing the ability to package the recombinant AAV genome, and provides us with valuable basic information for the development of efficient AAV packaging cell lines.
- 1 April 1999
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 90 (4) , 476-483
Efficient Production of Adeno‐associated Virus Vectors Using Split‐type Helper Plasmids
Adeno‐associated virus (AAV) vectors are potentially useful vehicles for the delivery of therapeutic genes into human cells. To determine the optimal expression pattern of AAV proteins (Rep78, Rep68, Rep52, Rep40, and Cap proteins) for packaging the recombinant AAV genome, helper plasmids were split into two portions. In this study, two sets of split‐type helper plasmids were prepared; i.e., 1) a Rep expression plasmid (pRep) and Cap expression plasmid (pCap), and 2) a large Rep expression plasmid (pR78/68) and small Rep plus Cap expression plasmid (pR52/40Cap). When AAV vectors were produced using these sets of split‐type helper plasmids at various ratios, the optimal ratio of (large) Rep expression plasmid and Cap expression plasmid was 1 to 9 for both sets. More importantly, the titers were comparable to or even higher than that of a conventional helper plasmid (pIM45) (4.9±2.1×1011 vector particles/10 cm dish for pRep and pCap; 2.9±1.6×1011 vector particles/10 cm dish for pR78/68 and pR52/40Cap; and 1.8±0.16×1011 particles/10 cm dish for pIM45). Western analysis of AAV proteins suggests that the expression of a relatively small amount of large Rep and a large amount of Cap is important for optimal vector production. The present study shows that the AAV helper plasmid can be split without losing the ability to package the recombinant AAV genome, and provides us with valuable basic information for the development of efficient AAV packaging cell lines.
- Open Access
- 15 November 1997
- Published by American Society of Hematology in Blood
- Vol. 90 (10) , 3884-3892
Development of a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Cells
To overcome the low efficiency of gene transfer into hematopoietic cells, we developed a novel system for selective expansion of transduced cells. To this end, we constructed a chimeric cDNA (GCRER) encoding the fusion protein between the granulocyte colony-stimulating factor receptor (G-CSFR) and the hormone-binding domain (HBD) of the estrogen receptor (ER) as a selective amplifier gene. Use of the intracellular signaling pathway of G-CSFR was considered to be appropriate, because G-CSF has the ability not only to stimulate the neutrophil production, but also to expand the hematopoietic stem/progenitor cell pool in vivo. To activate the exogenous G-CSFR signal domain selectively, the estrogen/ER-HBD system was used as a molecular switch in this study. When the GCRER gene was expressed in the interleukin-3 (IL-3)–dependent murine cell line, Ba/F3, the cells showed IL-3–independent growth in response to G-CSF or estrogen. Moreover, the Ba/F3 cells transfected with the Δ(5-195)GCRER, whose product lacks the extracellular G-CSF–binding domain, did not respond to G-CSF, but retained the ability for estrogen-dependent growth. Further, murine bone marrow cells transduced with the GCRER or Δ(5-195)GCRER gene with retroviral vectors formed a significant number of colonies in response to estrogen, as well as G-CSF, whereas estrogen did not stimulate colony formation by untransduced murine bone marrow cells. It is noteworthy that erythroid colonies were apparently formed by the bone marrow cells transduced with the GCRER gene in the presence of estrogen without the addition of erythropoietin, suggesting that the signals from the G-CSFR portion of the chimeric molecules do not preferentially induce neutrophilic differentiation, but just promote the differentiation depending on the nature of the target cells. We speculate that when the selective amplifier genes are expressed in the primitive hematopoietic stem cells, the growth signal predominates and that the population of transduced stem cells expands upon estrogen treatment, even if some of the cells enter the differentiation pathway. The present study suggests that this strategy is applicable to the in vivo selective expansion of transduced hematopoietic stem cells.
- 15 November 1997
- Published by American Society of Hematology in Blood
- Vol. 90 (10) , 3884-3892
Open AccessDevelopment of a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Cells
To overcome the low efficiency of gene transfer into hematopoietic cells, we developed a novel system for selective expansion of transduced cells. To this end, we constructed a chimeric cDNA (GCRER) encoding the fusion protein between the granulocyte colony-stimulating factor receptor (G-CSFR) and the hormone-binding domain (HBD) of the estrogen receptor (ER) as a selective amplifier gene. Use of the intracellular signaling pathway of G-CSFR was considered to be appropriate, because G-CSF has the ability not only to stimulate the neutrophil production, but also to expand the hematopoietic stem/progenitor cell pool in vivo. To activate the exogenous G-CSFR signal domain selectively, the estrogen/ER-HBD system was used as a molecular switch in this study. When the GCRER gene was expressed in the interleukin-3 (IL-3)–dependent murine cell line, Ba/F3, the cells showed IL-3–independent growth in response to G-CSF or estrogen. Moreover, the Ba/F3 cells transfected with the Δ(5-195)GCRER, whose product lacks the extracellular G-CSF–binding domain, did not respond to G-CSF, but retained the ability for estrogen-dependent growth. Further, murine bone marrow cells transduced with the GCRER or Δ(5-195)GCRER gene with retroviral vectors formed a significant number of colonies in response to estrogen, as well as G-CSF, whereas estrogen did not stimulate colony formation by untransduced murine bone marrow cells. It is noteworthy that erythroid colonies were apparently formed by the bone marrow cells transduced with the GCRER gene in the presence of estrogen without the addition of erythropoietin, suggesting that the signals from the G-CSFR portion of the chimeric molecules do not preferentially induce neutrophilic differentiation, but just promote the differentiation depending on the nature of the target cells. We speculate that when the selective amplifier genes are expressed in the primitive hematopoietic stem cells, the growth signal predominates and that the population of transduced stem cells expands upon estrogen treatment, even if some of the cells enter the differentiation pathway. The present study suggests that this strategy is applicable to the in vivo selective expansion of transduced hematopoietic stem cells.